{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:14Z","timestamp":1760028434313},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,5,24]],"date-time":"2002-05-24T00:00:00Z","timestamp":1022198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abciximab therapy improves clinical outcomes after percutaneous interventions for de novo coronary artery disease. We sought to determine whether clinical outcomes after percutaneous intervention for in\u2010stent restenosis are affected by abciximab administration. Between January 1996 and July 1999, 322 consecutive patients underwent percutaneous intervention for in\u2010stent restenosis; 157 patients received abciximab and 165 patients were treated without abciximab based on operator discretion. Baseline clinical and angiographic variables and type of percutaneous intervention were recorded. Follow\u2010up information was obtained and clinical endpoints were recorded. A multivariate analysis was performed to determine the independent variables associated with adverse clinical outcomes. Baseline clinical and angiographic variables were similar in both groups. Patients who received abciximab were more likely to be treated with rotational atherectomy and less likely to have only balloon angioplasty or repeat stenting. Mean follow\u2010up duration was 19 \u00b1 12 months. There were no significant differences in the incidence of angina\/myocardial infarction (29% vs. 30%; <jats:italic>P<\/jats:italic> = 0.9), target vessel revascularization (18% vs. 21%; <jats:italic>P<\/jats:italic> = 0.5), death (8% vs. 7%; <jats:italic>P<\/jats:italic> = 0.4), or major adverse cardiovascular events (38% vs. 39%; <jats:italic>P<\/jats:italic> = 0.9) in both groups. Abciximab administration was not an independent variable associated with adverse outcomes. In this observational study, clinical outcomes after percutaneous intervention for in\u2010stent restenosis did not seem to be affected by abciximab administration. Randomized trials are needed to identify the role of platelet glycoprotein IIb\/IIIa inhibitors in the management of in\u2010stent restenosis. Cathet Cardiovasc Intervent 2002;56:184\u2013187. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.10166","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T12:21:52Z","timestamp":1033906912000},"page":"184-187","source":"Crossref","is-referenced-by-count":4,"title":["Abciximab administration and clinical outcomes after percutaneous intervention for in\u2010stent restenosis"],"prefix":"10.1002","volume":"56","author":[{"given":"Ali","family":"Moustapha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abid R.","family":"Assali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Sdringola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Wamique","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. David","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Schroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvonimir","family":"Krajcer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar R.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Smalling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Vernon","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310801"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310802"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199703203361201"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90813-R"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11086-3"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90715-D"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)90126-0"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00190-8"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.9.2373"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a014698"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00128-2"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362401"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long\u2010term protection from myocardial ischemic events in a randomized trial of brief integrin beta 3 blockade with percutaneous coronary intervention: EPIC investigator group","volume":"278","author":"Topol EJ","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10018-7"},{"key":"e_1_2_5_16_2","first-page":"I162","article-title":"Long\u2010term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention","volume":"97","author":"Anderson K","year":"1997","journal-title":"Circulation"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0304(199811)45:3<332::AID-CCD27>3.0.CO;2-R"},{"key":"e_1_2_5_18_2","first-page":"21","article-title":"Device influence on outcome in the treatment of in\u2010stent restenosis with and without radiation: a subanalysis from the WRIST study","volume":"35","author":"Waksman R","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00150-2"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01231-1"},{"key":"e_1_2_5_21_2","first-page":"545","article-title":"Unexpected mortality reduction with abciximab for in\u2010stent restenosis","volume":"12","author":"Mukherjee D","year":"2000","journal-title":"J Invas Cardiol"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.10166","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.10166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:47:59Z","timestamp":1700394479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.10166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,24]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1002\/ccd.10166"],"URL":"https:\/\/doi.org\/10.1002\/ccd.10166","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,24]]}}}